胃腸および消化器系

抽象的な

Boceprevir in Mexico: Experience in a Series of Cases

José Antonio Mata-Marín, Jorge Luis Sandoval-Ramirez, Bulmaro Manjarrez-Tellez, Jesus Enrique Gaytán-Martínez and Alberto Chaparro-Sánchez

There are many new drugs for HCV treatment. First generation protease inhibitors are about to be discontinued. However in developing countries the likelihood of access to these new drugs is vague. As in other poor countries, in Mexico we only have peg interferon and ribavirin for HCV treatment and the costs of the new therapies are hard to fill. This is a report of the outcome in 30 patients who received triple therapy adding Boceprevir to peg interferon and Ribavirin as part of an extended-access program. As described elsewhere Latinos have lower response rates. This is the largest series of cases in Mexico City, and we would like to share this experience with other developing countries.